Uwe Staub - Epigenomics AG Insider

EPGNF -- USA Stock  

USD 2.68  0.0029  0.11%

  COO
Dr. Uwe Staub resigned as Chief Operating Officer at Epigenomics AG with effect from March 31, 2018, a position he has held since April 1, 2013. Prior to that, he served as Senior Vice President Research and Development Manufacturing of the Company from November 1, 2008. He was also granted procura and will take over the responsibility for medical affairs and customer support of the Company. Before joining the Company, Dr. Staub worked 14 years in the IVD industry for Abbott Diagnostics, Digene and Qiagen and gained experience in Operations, Quality and Regulatory Affairs as well as Product Development. He studied Biology at the JuliusMaximiliansUniversitaet Wuerzburg, Germany, and earned his Ph.D. degree in Biochemistry and Human Genetics.
  COO Since 2013  Ph.D    
49 30 243 450  http://www.epigenomics.com

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Similar Executives

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.

Epigenomics AG Leadership Team

Antje Zeise, Manager Investor Relations
Guenther Reiter, Member of the Supervisory Board
Gregory Hamilton, CEO
Ann Kessler, Member of the Supervisory Board
Heino Prondzynski, Chairman of the Supervisory Board
Helge Lubenow, Member of the Supervisory Board
Thomas Taapken, CEO, CFO and Member of Executive Board
Annett Dietrich, Manager Human Resources
Noel Doheny, CEO of Epigenomics Inc.
Uwe Staub, COO and Member of Executive Board
Albert Weber, Sr. VP of Fin., Accounting and Controlling
Nicola HennebergBusse, Vice President - Business Development
Jorge Garces, President Chief Scientific Officer
Nicholas Potter, Director Reimbursement and Medical Affairs
Peter Vogt, Investor & Public Relations Officer

Stock Performance Indicators

Did you try this?

Run Equity Analysis Now
   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Equity Analysis

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Epigenomics AG and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">